Nicola Giangregorio

Dr. Nicola Giangregorio

Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, Bari, Puglia, Italy
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
ATAnnamaria Tonazzi
Annamaria Tonazzi
NGNicola Giangregorio
Nicola Giangregorio
lara consolelara console
lara console
Ferdinando PalmieriFerdinando Palmieri
Ferdinando Palmieri
Cesare IndiveriCesare Indiveri
Cesare Indiveri
The SLC25A20 transporter, also known as carnitine acyl-carnitine carrier (CAC), catalyzes the transport of short, medium and long carbon chain acyl-carnitines across the mitochondrial inner membrane in exchange for carnitine. The 30-year story of the protein responsible for this function started with its purification from rat liver mitochondria. Even though its 3D structure is not yet available, CAC is one of the most deeply characterized transport proteins of the inner mitochondrial membrane. Other than functional, kinetic and mechanistic data, post-translational modifications regulating the transport activity of CAC have been revealed. CAC interactions with drugs or xenobiotics relevant to human health and toxicology and the response of the carrier function to dietary compounds have been discovered. Exploiting combined approaches of site-directed mutagenesis with chemical targeting and bioinformatics, a large set of data on structure/function relationships have been obtained, giving novel information on the molecular mechanism of the transport catalyzed by this protein.

25 November 2019 in Molecules
Verified
Journal Article
Open access
PDF file
IBISABELLA BOLOGNINO
ISABELLA BOLOGNINO
NGNicola Giangregorio
Nicola Giangregorio
Leonardo PisaniLeonardo Pisani
Leonardo Pisani
Modesto de CandiaModesto de Candia
Modesto de Candia
Rosa PurgatorioRosa Purgatorio
Rosa Purgatorio
MCMarco Catto
Marco Catto
The orphan drug dantrolene (DAN) is the only therapeutic treatment for malignant hyperthermia (MH), a pharmacogenetic pathology affecting 0.2 over 10,000 people in the EU. It acts by inhibiting ryanodine receptors, which are responsible for calcium recruitment in striatal muscles and brain. Because of its involvement in calcium homeostasis, DAN has been successfully investigated for its potential as neuroprotecting small molecule in several animal models of Alzheimer’s disease (AD). Nevertheless, its effects at a molecular level, namely on putative targets involved in neurodegeneration, are still scarcely known. Herein, we present a prospective study on repurposing of DAN involving, besides the well-known calcium antagonism, inhibition of monoamine oxidase B and acetylcholinesterase, cytoprotection from oxidative insult, and activation of carnitine/acylcarnitine carrier, as concurring biological activities responsible for neuroprotection.


17 September 2022 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
NGNicola Giangregorio
Nicola Giangregorio
Ciro Leonardo PierriCiro Leonardo Pierri
Ciro Leonardo Pierri
ATAnnamaria Tonazzi
Annamaria Tonazzi
GIGiovanna Incampo
Giovanna Incampo
VTVincenzo Tragni
Vincenzo Tragni
CICesare Indiveri
Cesare Indiveri

13 February 2020 in Molecules
Verified
Journal Article
Open access
PDF file
NGNicola Giangregorio
Nicola Giangregorio
ATAnnamaria Tonazzi
Annamaria Tonazzi
lara consolelara console
lara console
MPMario Prejanò
Mario Prejanò
Marino TizianaMarino Tiziana
Marino Tiziana
Cesare IndiveriCesare Indiveri
Cesare Indiveri
The effect of copper on the mitochondrial carnitine/acylcarnitine carrier (CAC) was studied. Transport function was assayed as [3H]carnitine/carnitine antiport in proteoliposomes reconstituted with the native protein extracted from rat liver mitochondria or with the recombinant CAC over-expressed in E. coli. Cu2+ (as well as Cu+) strongly inhibited the native transporter. The inhibition was reversed by GSH (reduced glutathione) or by DTE (dithioerythritol). Dose-response analysis of the inhibition of the native protein was performed from which an IC50 of 1.6 µM for Cu2+ was derived. The mechanism of inhibition was studied by using the recombinant WT or Cys site-directed mutants of CAC. From the dose-response curve of the effect of Cu2+ on the recombinant protein, an IC50 of 0.28 µM was derived. Inhibition kinetics revealed a non-competitive type of inhibition by Cu2+. However, a substrate protection experiment indicated that the interaction of Cu2+ with the protein occurred in the vicinity of the substrate-binding site. Dose-response analysis on Cys mutants led to much higher IC50 values for the mutants C136S or C155S. The highest value was obtained for the C136/155S double mutant, indicating the involvement of both Cys residues in the interaction with Cu2+. Computational analysis performed on the WT CAC and on Cys mutants showed a pattern of the binding energy mostly overlapping the binding affinity derived from the dose-response analysis. All the data concur with bridging of Cu2+ with the two Cys residues, which blocks the conformational changes required for transport cycle.

Verified
Journal Article
Open access
PDF file
MICHELE GALLUCCIOMICHELE GALLUCCIO
MICHELE GALLUCCIO
lara consolelara console
lara console
Lorena PochiniLorena Pochini
Lorena Pochini
Mariafrancesca ScaliseMariafrancesca Scalise
Mariafrancesca Scalise
NGNicola Giangregorio
Nicola Giangregorio
Cesare IndiveriCesare Indiveri
Cesare Indiveri
Ten percent of human genes encode for membrane transport systems, which are key components in maintaining cell homeostasis. They are involved in the transport of nutrients, catabolites, vitamins, and ions, allowing the absorption and distribution of these compounds to the various body regions. In addition, roughly 60% of FDA-approved drugs interact with membrane proteins, among which are transporters, often responsible for pharmacokinetics and side effects. Defects of membrane transport systems can cause diseases; however, knowledge of the structure/function relationships of transporters is still limited. Among the expression of hosts that produce human membrane transport systems, E. coli is one of the most favorable for its low cultivation costs, fast growth, handiness, and extensive knowledge of its genetics and molecular mechanisms. However, the expression in E. coli of human membrane proteins is often toxic due to the hydrophobicity of these proteins and the diversity in structure with respect to their bacterial counterparts. Moreover, differences in codon usage between humans and bacteria hamper translation. This review summarizes the many strategies exploited to achieve the expression of human transport systems in bacteria, providing a guide to help people who want to deal with this topic.